On the other hand, non-peptide caspase inhibitors, such as MJL-001i, MJL-002i, and MJL-003i, are used for treatment and/or prophylaxis of HD by blocking the cleavage of Htt mediated by caspase-3 or caspase-6. This evidence concerns the gene CASP6 and Huntington disease.